False
December 23, 2020
DURYSTA™ (bimatoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT) (1). The intracameral implant is making the case for sustained drug delivery.
1 min read
September 7, 2019
The winners of the ICO-Allergan Advanced Research Fellowship… in conversation
1 min read
July 31, 2019
Matias Iglicki has been awarded a $50,000 research grant by the ICO-Allergan program
1 min read
False